Total medical devices industry M&A deals worth $28.2bn were announced in North America in November 2022, led by Johnson & Johnson’s $16.6bn acquisition of Abiomed, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 22112.6% over the previous month of $127m and a rise of 355.7% when compared with the last 12-month average of $6.19bn.
North America held a 100.00% share of the global medical devices industry M&A deal value that totalled $28.21bn in November 2022. With a 100.00% share and deals worth $28.21bn, the US was the top country in North America’s M&A deal value across medical devices industry.
In terms of M&A deal activity, North America recorded 31 deals during November 2022, marking an increase of 29.17% over the previous month and a rise of 10.71% over the 12-month average. The US recorded 26 deals during the month.
North America medical devices industry M&A deals in November 2022: Top deals
The top five medical devices industry M&A deals accounted for 99.9% of the overall value during November 2022.
The combined value of the top five medical devices deals stood at $28.19bn, against the overall value of $28.2bn recorded for the month.
The top five medical devices industry M&A deals of November 2022 tracked by GlobalData were:
1) Johnson & Johnson’s $16.6bn acquisition deal with Abiomed
2) The $8.9bn acquisition of Summit Health by VillageMD
3) WerfenLife’s $2bn acquisition deal with Immucor
4) The $615m acquisition of Apollo Endosurgery by Boston Scientific
5) Myriad Genetics’s $75m acquisition deal with Gateway Genomics
